Clinical trial
An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study (REScUE-OLE)
NCT05299931 is registered in ClinicalTrials.gov with Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study (REScUE-OLE)
- Lead sponsor
- Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 10, 2021
- Completion date
- May 29, 2026
- Enrollment
- 41 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.